UROGEN PHARMA LTD (URGN) — insider trading
Health Care · NASDAQ
UROGEN PHARMA LTD (URGN) has 29 reported SEC Form 4 insider transactions in our data, including 7 open-market sales among the most recent 29 (latest 2026-09-08).
Recent Form 4 transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026-09-08 | Smith Jason Drew | Officer (General Counsel) | Open-market sale | 1,519 | $42.54 | $64.6K | Form 4 |
| 2026-09-08 | Schoenberg Mark | Officer (Chief Medical Officer) | Open-market sale | 871 | $42.92 | $37.4K | Form 4 |
| 2026-09-07 | Smith Jason Drew | Officer (General Counsel) | Option exercise / conversion (derivative) | 3,334 | — | $0 | Form 4 |
| 2026-09-07 | Smith Jason Drew | Officer (General Counsel) | Option exercise / conversion | 3,334 | — | — | Form 4 |
| 2026-09-07 | Schoenberg Mark | Officer (Chief Medical Officer) | Option exercise / conversion (derivative) | 1,667 | — | $0 | Form 4 |
| 2026-09-07 | Schoenberg Mark | Officer (Chief Medical Officer) | Option exercise / conversion | 1,667 | — | — | Form 4 |
| 2026-08-26 | Robinson James A. Jr. | Director | Option exercise / conversion (derivative) | 2,000 | — | $0 | Form 4 |
| 2026-08-26 | Robinson James A. Jr. | Director | Option exercise / conversion | 2,000 | — | — | Form 4 |
| 2026-08-20 | Schoenberg Mark | Officer (Chief Medical Officer) | Open-market sale | 60,677 | $47.05 | $2.85M | Form 4 |
| 2026-07-09 | Schoenberg Mark | Officer (Chief Medical Officer) | Open-market sale | 10,000 | $40.00 | $400.0K | Form 4 |
| 2026-06-22 | Belldegrun Arie | Director | Grant / award / vesting (derivative) | 20,000 | — | $0 | Form 4 |
| 2026-06-22 | WEN LEANA | Director | Grant / award / vesting (derivative) | 8,000 | — | $0 | Form 4 |
| 2026-06-22 | WEN LEANA | Director | Grant / award / vesting (derivative) | 10,000 | — | $0 | Form 4 |
| 2026-06-22 | BUTITTA CYNTHIA M | Director | Grant / award / vesting (derivative) | 8,000 | — | $0 | Form 4 |
| 2026-06-22 | BUTITTA CYNTHIA M | Director | Grant / award / vesting (derivative) | 10,000 | — | $0 | Form 4 |
| 2026-06-22 | Holden Stuart | Director | Grant / award / vesting (derivative) | 20,000 | — | $0 | Form 4 |
| 2026-06-22 | Robinson James A. Jr. | Director | Grant / award / vesting (derivative) | 8,000 | — | $0 | Form 4 |
| 2026-06-22 | Robinson James A. Jr. | Director | Grant / award / vesting (derivative) | 10,000 | — | $0 | Form 4 |
| 2026-06-22 | Wildman Daniel George | Director | Grant / award / vesting (derivative) | 8,000 | — | $0 | Form 4 |
| 2026-06-22 | Wildman Daniel George | Director | Grant / award / vesting (derivative) | 10,000 | — | $0 | Form 4 |
| 2026-06-22 | Schoenberg Mark | Officer (Chief Medical Officer) | Open-market sale | 10,000 | $35.01 | $350.1K | Form 4 |
| 2026-06-08 | Schoenberg Mark | Officer (Chief Medical Officer) | Option exercise / conversion (derivative) | 10,000 | — | $0 | Form 4 |
| 2026-06-08 | Schoenberg Mark | Officer (Chief Medical Officer) | Open-market sale | 5,222 | $27.30 | $142.6K | Form 4 |
| 2026-06-08 | Schoenberg Mark | Officer (Chief Medical Officer) | Option exercise / conversion | 10,000 | — | — | Form 4 |
| 2026-05-26 | Robinson James A. Jr. | Director | Option exercise / conversion (derivative) | 2,000 | — | $0 | Form 4 |
| 2026-05-26 | Robinson James A. Jr. | Director | Option exercise / conversion | 2,000 | — | — | Form 4 |
| 2026-05-08 | Schoenberg Mark | Officer (Chief Medical Officer) | Open-market sale | 10,000 | $30.00 | $300.0K | Form 4 |
| 2025-02-26 | Robinson James A. Jr. | Director | Option exercise / conversion (derivative) | 2,000 | — | $0 | Form 4 |
| 2025-02-26 | Robinson James A. Jr. | Director | Option exercise / conversion | 2,000 | — | — | Form 4 |
Ask the chat about URGN's insider activity →
Transaction types are the SEC Form 4 codes: open-market purchases (P) and sales (S) are the only rows that reflect open-market conviction. Awards/vesting (A), option exercises (M/X/C), shares withheld for taxes (F) and gifts (G) are compensation or mechanical, not buying or selling on the open market. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan); open-market buying is not a recommendation to buy. Informational only — not financial advice.
Source: SEC EDGAR Form 3/4/5. See the full company profile: UROGEN PHARMA LTD (URGN).
Last updated 2026-09-08 (most recent filing date).
Informational only — NOT financial advice. Insider filings are sourced from SEC EDGAR and shown with their reported dates.